However, an evaluation of the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2020 found a significantly increased (proportional reporting ratio: 9.86) pancreatic cancer cases associated with GLP‐1 RAs compared to the other glucose‐lowering agents analysed in the study [22]. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.